CCND1 and embryonal neoplasm: To characterize the effect of SRX3177 in detail, we measured cytotoxic activity of this inhibitor in a cyclin D1-dependent hematologic malignancy (mantle cell lymphoma), a MYC-dependent embryonal tumor (neuroblastoma), and a PI3K-dependent solid tumor (hepatocellular carcinoma) (Fig. 1f–h).